UBS AG reported on Essilor International (EPA:EI), upping its price target to 139.00EUR earlier today
- Updated: October 14, 2016
Boasting a price of 110.25EUR, Essilor International (EPA:EI) traded 0.00% even on the day. The last stock close price is up 0.00% from the two hundred day average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same period. Essilor International has recorded a 50-day average of 0.00EUR and a 200-day moving average of 0.00EUR. 0 shares of the stock traded hands, down from an average trading volume of 0
UBS AG raised the target price of Essilor International (EPA:EI) to 139.00EUR indicating a possible upside of 0.26%.
On Thursday October 13, 2016, UBS AG released a statement for Essilor International (EPA:EI) raised the target price from 0.00EUR to 139.00EUR. At the time, this indicated a possible upside of 0.26%.
Essilor International has 52 week low of 0.00EUR and a 52 week high of 0.00EUR and has a market capitalization of 0 EUR.
Brief Synopsis On Essilor International (EPA:EI)
Essilor International SA, formerly Essilor International Compagnie Generale D'Optique SA, is an ophthalmic optics company. The Company designs, manufactures and markets a range of lenses to improve and protect eyesight. It also develops and markets equipment for prescription laboratories, and instruments and services for eye care professionals. It operates through three segments: Lenses and Optical Instruments, Equipment, and Sunglasses & Readers. It is a North American provider of non-prescription reading glasses. It also sells non-prescription sunglasses. It has approximately 32 plants, over 490 prescription laboratories, edging facilities and local distribution centers, and over five research and development centers across the world. The Company designs, manufactures and customizes corrective lenses. The Company provides a range of lenses for correcting myopia, hyperopia, astigmatism and presbyopia. It operates through MyOptique Group.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.